You are here

  • Home
  • Archive
  • Volume 9, Issue 2
  • Correction: Long-term safety and efficacy of upadacitinib or adalimumab in patients with rheumatoid arthritis: results through 3 years from the SELECT-COMPARE study

Citation Tools

Article menu

See original article:

Download PDFPDF

Correction
Correction: Long-term safety and efficacy of upadacitinib or adalimumab in patients with rheumatoid arthritis: results through 3 years from the SELECT-COMPARE study

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:
Correction: Long-term safety and efficacy of upadacitinib or adalimumab in patients with rheumatoid arthritis: results through 3 years from the SELECT-COMPARE study
RMD Open 2023;9:e002012corr1. doi: 10.1136/rmdopen-2021-002012corr1